Intelligence · Clinical Development
Pipeline search results
Programs matching “bgb-” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 59 pipeline programs matching "bgb-" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
BGB-11417 for Previously Untreated Chronic Lymphocytic Leukemia
BEONE MEDICINES AUS PTY LTD
Previously Untreated Chronic Lymphocytic Leukemia
1 trial -
BGB-11417-302
BEONE MEDICINES AUS PTY LTD
relapsed or refractory mantle cell lymphoma (R/R MCL)
1 trial -
BGB-11417-303CLL-RR1
BEONE MEDICINES AUS PTY LTD
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
BGB-11417-304
BEONE MEDICINES AUS PTY LTD
treatment-naive Chronic Lymphocytic Leukemia
1 trial -
BGB-16673
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia
2 trials -
BGB-16673
BEONE MEDICINES AUS PTY LTD
CLL
1 trial -
BGB-16673-302
BEONE MEDICINES AUS PTY LTD
Chronic lymphotic leukemia and Small Lymphocytic lymphoma
1 trial -
BGB-16673-304
BEONE MEDICINES AUS PTY LTD
Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL)
1 trial -
BGB-3111
BeiGene
Waldenström's Macroglobulinemia
1 trial -
BGB-3111-304
BEONE MEDICINES AUS PTY LTD
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
BGB-3111-306
BEONE MEDICINES AUS PTY LTD
Mantle Cell Lymphoma
1 trial -
BGB-43395
BEONE MEDICINES AUS PTY LTD
HR+/HER2- Breast Cancer
1 trial -
BGB-A317-290-LTE1
BEONE MEDICINES AUS PTY LTD
Solid tumors and hamatological malignancies
1 trial -
BGB-A317-316
BEONE MEDICINES AUS PTY LTD
Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
1 trial -
BGB-A317-A1217-302
BeiGene
Locally advanced, unresectable, or metastatic non small cell lung cancer
1 trial -
Zanubrutinib
BEONE MEDICINES AUS PTY LTD
B-cell malignancies
1 trial -
BGB-10188
BEONE MEDICINES AUS PTY LTD
Chronic Lymphocytic Leukemia
1 trial -
BGB-11417
BEONE MEDICINES AUS PTY LTD
Acute Myeloid Leukemia
1 trial -
BGB-11417
BEONE MEDICINES AUS PTY LTD
Leukemia
1 trial -
BGB-11417-103
BEONE MEDICINES AUS PTY LTD
Myeloid malignancies (acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN.
1 trial -
BGB-11417-105
BEONE MEDICINES AUS PTY LTD
relapsed or refractory multiple myeloma
1 trial -
BGB-11417-108
BEONE MEDICINES AUS PTY LTD
previously untreated chronic lymphocytic leukemia (CLL)
1 trial -
BGB-11417-203
BEONE MEDICINES AUS PTY LTD
previously untreated WM, Relapsed/Refractory Waldenström’s Macroglobulinemia
1 trial -
BGB-11417-204
BEONE MEDICINES AUS PTY LTD
Previously Untreated Chronic Lymphocytic Leukemia
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.